timothy sykes logo
BIAF Stock Jumps As Federal Deal Fuels CyPath Lung Momentum Thumbnail
G Google News

BIAF Stock Jumps As Federal Deal Fuels CyPath Lung Momentum

TIM SYKES•UPDATED SEP. 9, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

bioAffinity Technologies Inc. stocks have been trading up by 18.73 percent following highly optimistic coverage of its diagnostic platform.

Key Takeaways For BIAF Traders

  • A new nationwide AvMEDICAL distribution deal opens federal healthcare channels for CyPath Lung, including direct access to veterans and other government-covered patients.
  • The AvMEDICAL partnership plugs BIAF into existing government procurement and IDIQ contracting, rather than building a federal sales engine from scratch.
  • bioAffinity Technologies is pushing CyPath Lung beyond early detection into post-treatment surveillance of lung cancer survivors alongside standard imaging.
  • BIAF plans a detailed corporate update and one‑on‑one meetings at the H.C. Wainwright Global Investment Conference, spotlighting CyPath Lung adoption and platform expansion.

Candlestick Chart

Live Update At 09:18:41 EDT: On Wednesday, September 09, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 18.73%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has been trading like a small-cap biotech on the move. In late August 2026, bioAffinity Technologies shares sat under $5. Then, in just a few sessions, BIAF ripped from $4.56 on 2026/08/31 to a high of $20.35 on 2026/09/04 before closing at $15.27. The most recent close at $8.93 on 2026/09/08 still leaves BIAF up sharply from August levels, but shows traders already riding a boom‑and‑pullback pattern.

Under the hood, bioAffinity Technologies is still an early‑stage commercial story. Revenue over the last period sits around $6.11M, but margins are deeply negative, with EBITDA and net income firmly in the red. Profitability ratios scream “development phase,” not steady cash generator. BIAF’s price‑to‑sales near 1.6 and price‑to‑book around 2.4 are typical for a speculative biotech trying to scale.

More Breaking News

On the balance sheet, BIAF runs with moderate leverage and a current ratio near 1.4, which gives some breathing room but not a fortress. Cash flow shows heavy operating burn partly offset by stock issuance. For traders, that means BIAF’s chart is likely to react more to news and momentum than to fundamentals until CyPath Lung revenue meaningfully ramps.

Why Traders Are Watching BIAF Now

BIAF has the kind of catalyst stack that active traders look for. The first big piece is the nationwide federal healthcare distribution agreement with AvMEDICAL. This deal gives bioAffinity Technologies direct access to U.S. Department of Veterans Affairs and other federal healthcare systems for its CyPath Lung noninvasive lung cancer diagnostic. Instead of slowly knocking on agency doors, BIAF can tap into AvMEDICAL’s existing government‑focused sales force and IDIQ contracting channels.

For trading purposes, this matters. Federal systems are slow to move, but once a product is embedded, volumes can stabilize and grow over years. If BIAF executes, that AvMEDICAL channel can turn CyPath Lung from a niche test into a regular tool for veterans and other federal beneficiaries. Traders are betting on that potential, which helps explain the violent move from sub‑$5 levels to a $20.35 intraday spike on 2026/09/04.

At the same time, bioAffinity Technologies is not just chasing more customers; it is broadening the job CyPath Lung can do. The company is advancing its sputum‑based test beyond early detection into post‑treatment surveillance of lung cancer survivors. That means using CyPath Lung alongside imaging to monitor for recurrence or new primary cancers in a high‑risk population that currently relies mostly on periodic scans.

If this surveillance use case gains traction, each patient could generate more tests over a longer period, lifting utilization per person. For BIAF traders, that translates into a bigger long‑term revenue opportunity than diagnosis alone. Layer on the upcoming corporate update and one‑on‑one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, and you have a clear visibility catalyst. Conferences like this often spark headlines and fresh trading volume as management walks through milestones, CyPath Lung adoption trends, and platform plans.

Conclusion

BIAF is acting like a textbook news‑driven biotech runner. The federal AvMEDICAL agreement gives bioAffinity Technologies a credible commercial path into VA and other government healthcare systems, while the push into post‑treatment lung cancer surveillance enlarges the strategic map for CyPath Lung. None of this changes the fact that bioAffinity Technologies is still losing money and burning cash, but it does change the narrative around future revenue potential.

For short‑term traders, the recent chart shows exactly what’s possible when a small float stock like BIAF meets real news catalysts: a vertical spike, sharp pullbacks, and multiple intraday swings big enough to matter. The intraday tape already shows BIAF whipping between the high $8s and low $11s, offering range for disciplined day and swing trading.

The key is staying data‑driven. Watch how BIAF talks about federal ordering timelines, adoption metrics, and any early signals from the surveillance push at the 2026/09/03 H.C. Wainwright appearance. As Tim Sykes loves to say, “The patterns repeat, but you have to study every detail and cut losses quickly when the pattern breaks.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” For bioAffinity Technologies and BIAF traders, that means respecting both the upside potential and the very real downside risk that comes with a volatile, early‑stage biotech story.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”